Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

File Analysis of Falling Patients: Are Drugs Frequently Involved (ADOPAC)

5. marts 2021 opdateret af: Groupe Hospitalier Paris Saint Joseph

The damage caused by patient falls is a major public health problem, due to the large and growing number of people concerned, the potentially serious consequences but also the financial cost generated by their care.

These consequences can be physical as well as psychological. Fractures and pain are the first consequences that come to mind, but many others should be mentioned: post-fall syndrome, loss of autonomy or even entering an institution, fear of falling, loss of confidence in itself.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

During 2018, 285 reports of falls were counted within the Paris Saint-Joseph Hospital Group (GhPSJ). Reducing these falls is one of the institutional goals. A dedicated working group has been created to put in place preventive and corrective measures.

These falls can be caused by many factors to the patient:

  1. Intrinsic:

    • History of a fall,
    • pathologies (Parkinson's or Alzheimer's disease),
    • hearing and visual disturbances,
    • urinary incontinence.
  2. extrinsic:

    • Unsuitable shoes
    • unsuitable habitat,
    • slippery floors (eg bathroom).

Among the intrinsic factors, polypharmacy is also found. It has been established that certain drug classes are at risk of falling, in particular psychotropic drugs (benzodiazepines, hypnotics, anxiolytics, antidepressants, neuroleptics) which promote sedation and dizziness, hypoglycemic drugs which cause hypoglycaemia in diabetic patients on -treated or antihypertensive drugs causing hypotension.

It is now clearly established that drug adherence to treatment is poor in cities, giving rise to omissions but also sometimes to overconsumption of certain drugs, including psychotropic drugs.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

52

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Ile De France
      • Paris, Ile De France, Frankrig, 75014
        • Groupe Hospitalier Paris Saint-Joseph

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

From Monday to Friday, the study will be offered to patients selected consecutively and who have fallen within the previous 24 hours (between 7.55 a.m. the day before and 7.55 a.m. the next day).

Beskrivelse

Inclusion Criteria:

  • Major patient
  • French-speaking patient
  • Patient hospitalized within the Paris Saint-Joseph Hospital Group
  • Patient who fell during hospitalization and for whom a fall report has been completed

Exclusion Criteria:

  • Patients in the process of therapeutic limitation
  • Patient under guardianship or curatorship
  • Patient deprived of liberty
  • Patient objecting to participation in the study
  • Patient under legal protection

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Patients

From Monday to Friday, the study will be offered to patients selected consecutively and who have fallen within the previous 24 hours (between 7.55 a.m. the day before and 7.55 a.m. the next day).

After delivery of the written information note to the patient, the investigating physician answers the patient's questions and accepts his non-objection. The patient should be given sufficient time to think things through to make the decision to participate in the study.

Its non-opposition will be traced in the computerized medical file created on the day of its inclusion in the protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol.

Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To assess the prevalence of falls associated with one or more risk factors for drug iatrogenism within the Paris Saint-Joseph Hospital Group.
Tidsramme: 1 week
Percentage of falls involving one or more drugs at risk of falling
1 week

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
List the drug treatments at risk taken by patients who fall
Tidsramme: 1 week
To list the drug treatments taken by the patients who fall: carrying out the patient's drug assessment
1 week
Evaluate the relevance of drug prescriptions in patients who fall
Tidsramme: 1 week
Average number of inappropriate medication prescriptions per patient
1 week
Evaluate the overall compliance of falling patients
Tidsramme: 1 week
Average compliance score in patients who fall
1 week

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Elodie MENAGE, Groupe Hospitalier Paris Saint Joseph

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

18. april 2019

Primær færdiggørelse (Faktiske)

15. oktober 2019

Studieafslutning (Faktiske)

28. februar 2021

Datoer for studieregistrering

Først indsendt

1. marts 2021

Først indsendt, der opfyldte QC-kriterier

5. marts 2021

Først opslået (Faktiske)

8. marts 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. marts 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. marts 2021

Sidst verificeret

1. marts 2021

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • ADOPAC

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Efterårspatienter

Kliniske forsøg med No intervention

3
Abonner